Novo Nordisk Faces DKK350 Price Target Cut and Lawsuit Over $49 Wegovy Knockoffs
Bank of America reduced its Novo Nordisk DKK price target to 350 from 400 and cut 2026 EPS forecasts by 7–10% after management signaled weaker guidance. Novo Nordisk announced plans to pursue regulatory and legal action against Hims & Hers for offering unapproved compounded Wegovy at $49 per month, warning of safety and IP risks.
1. Analyst Price Target Cut
On February 5, Bank of America cut its Novo Nordisk price target to DKK 350 from DKK 400 and trimmed 2026 EPS forecasts by 7–10% following management’s disclosure of softer full-year guidance, reflecting concerns over slowing sales momentum in key markets.
2. Legal Action Over Compounded Pills
Novo Nordisk condemned Hims & Hers for marketing compounded copies of its FDA-approved Wegovy pill at an introductory $49 monthly price, labeling the practice “illegal mass compounding” and announcing imminent regulatory and legal measures to protect patient safety, intellectual property, and the drug approval framework.
3. Insider Trading Disclosures
In a routine compliance announcement, Novo Nordisk disclosed that board members, executives and their associated persons reported share transactions on February 10 in accordance with Article 19 of Regulation No. 596/2014, ensuring transparency of insider dealings.